Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemDiv and Nerviano Medical Sciences have entered into collaboration to optimize and develop hits for Nerviano's drug targets.
Subscribe to our email newsletter
The hits identified from Nerviano Medical Sciences (NMS) HT screening campaign will be optimized in terms of their potency, selectivity, in-vitro ADME profile with the subsequent progression into a lead optimisation program.
A dedicated team of ChemDiv’s chemists and biologists will work on this program in close collaboration with NMS. ChemDiv will receive fees for services carried out and milestone payment for the successful performance of the program.
Giampiero Duglio, CEO of Nerviano, said: “This new agreement is a significant step forward in the exploitation of our project pipeline. We believe ChemDiv’s contribution will represent a major upside in our commitment to push into the clinic, high quality chemical candidates intended to inhibit key cancer molecular targets.”